Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Mosaic Immunoengineering Inc

Healthcare US CPMV

0.674USD
0.00(0%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.690.69
LowHigh

52 Week Range

0.251.05
LowHigh

Fundamentals

  • Previous Close 0.67
  • Market Cap2.38M
  • Volume100
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-05-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-05-31 2022-12-31
Income before tax -0.68545M -0.91958M -1.00584M -2.37847M -2.37847M
Minority interest - - - - -
Net income -0.68785M -0.92198M -1.00823M -2.38087M -2.38087M
Selling general administrative 0.55M 0.70M 0.96M 1.58M 1.58M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - - - -2.62752M -2.62752M
Ebitda - - - -2.22689M -2.22689M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.61612M -0.87965M -1.39977M -2.62752M -2.62752M
Other operating expenses - - - - -
Interest expense 0.08M 0.08M 0.09M 0.15M 0.15M
Tax provision 0.00240M 0.00240M 0.00240M 0.00240M 0.00240M
Interest income 0.00001M 0.00001M 0.00341M 0.00003M 0.00003M
Net interest income -0.08333M -0.08193M -0.08577M -0.15155M -0.15155M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.00240M 0.00240M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.62M 0.88M 1.40M 2.63M 2.63M
Cost of revenue - - - - -
Total other income expense net 0.01M 0.04M 0.48M 0.40M 0.40M
Discontinued operations - - - - -
Net income from continuing ops -0.68785M -0.92198M -1.00823M -2.38087M -2.38087M
Net income applicable to common shares - - - -2.38087M -2.38087M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-05-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-05-31 2022-12-31
Total assets 0.02M 0.14M 0.18M 0.26M 0.26M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.03M 0.02M 0.04M 0.04M
Total liab 7.50M 6.93M 6.05M 5.15M 5.15M
Total stockholder equity -7.47602M -6.78817M -5.87106M -4.88476M -4.88476M
Deferred long term liab - - - - -
Other current liab 0.18M 0.18M 0.18M 0.22M 0.22M
Common stock - - - 0.00007M 0.00007M
Capital stock 0.00007M 0.00007M 0.00007M 0.00007M 0.00007M
Retained earnings -9.52617M -8.83832M -7.91634M -6.90810M -6.90810M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.00362M 0.12M 0.16M 0.22M 0.22M
Cash and equivalents - - - - -
Total current liabilities 6.03M 5.54M 4.73M 3.92M 3.92M
Current deferred revenue - - - - -
Net debt 1.66M 1.48M 1.16M 1.01M 1.01M
Short term debt - - - - -
Short long term debt 0.20M 0.20M - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets 0.02M 0.14M 0.18M 0.26M 0.26M
Long term investments - - - - -
Net tangible assets - - - -4.88476M -4.88476M
Short term investments - - - - -
Net receivables - - - - -
Long term debt 1.47M 1.39M 1.32M 1.23M 1.23M
Inventory - - - - -
Accounts payable 0.13M 0.13M 0.12M 0.13M 0.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-05-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-05-31 2022-12-31
Investments - 0.00000M 0.43M 0.34M 0.34M
Change to liabilities - - - 0.02M 0.02M
Total cashflows from investing activities - - - 0.34M 0.34M
Net borrowings 0.00000M 0.20M 0.00000M 0.34M 0.34M
Total cash from financing activities 0.00000M 0.20M 0.00000M 0.34M 0.34M
Change to operating activities - - - 1.62M 1.62M
Net income -0.68785M -0.92198M -1.00823M -2.38087M -2.38087M
Change in cash -0.11140M -0.04116M -0.06447M -0.00550M -0.00550M
Begin period cash flow 0.12M 0.16M 0.22M 0.23M 0.23M
End period cash flow 0.00362M 0.12M 0.16M 0.22M 0.22M
Total cash from operating activities -0.11140M -0.24116M -0.49747M -0.69013M -0.69013M
Issuance of capital stock - - - - -
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -
Change to netincome - - - 0.05M 0.05M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.50M 0.57M 0.88M 1.64M 1.64M
Stock based compensation 0.00000M 0.00487M 0.02M 0.30M 0.30M
Other non cash items 0.07M 0.11M 0.09M -0.19142M -0.19142M
Free cash flow -0.11140M -0.24116M -0.49747M -0.69013M -0.69013M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CPMV
Mosaic Immunoengineering Inc		 - -% 0.67 - 10.81 96.57 9.33 72.63 105.80
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. It engages in pursuing new product candidates and platforms to build a new pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.

Mosaic Immunoengineering Inc

9114 Adams Avenue, Huntington Beach, CA, United States, 92646

Key Executives

Name Title Year Born
Mr. Steven W. King Chairman, Pres & CEO 1964
Mr. Paul J. Lytle CPA Exec. VP, CFO, Sec. & Director 1968
Dr. Nicole Franziska Steinmetz Ph.D. Acting Chief Scientific Officer & Director 1980
Jay Carlson Sr. Mang. of Investor Relations NA
Mr. Joseph S. Shan M.P.H. Head of Clinical Operations 1973
Dr. Marvin R. Garovoy M.D. Head of Medical Immuno-Oncology 1944
Cyril Empig Ph.D. Head of Vaccine Devel. NA
Mr. Steven W. King Chairman of the Board, President, CFO & CEO 1964
Mr. Paul J. Lytle CPA Secretary 1968
Cyril Empig Ph.D. Head of Vaccine Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions